JP2011500035A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500035A5 JP2011500035A5 JP2010529192A JP2010529192A JP2011500035A5 JP 2011500035 A5 JP2011500035 A5 JP 2011500035A5 JP 2010529192 A JP2010529192 A JP 2010529192A JP 2010529192 A JP2010529192 A JP 2010529192A JP 2011500035 A5 JP2011500035 A5 JP 2011500035A5
- Authority
- JP
- Japan
- Prior art keywords
- codon
- polynucleotide
- immune response
- synonymous
- construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091033319 polynucleotide Proteins 0.000 claims description 70
- 102000040430 polynucleotide Human genes 0.000 claims description 70
- 239000002157 polynucleotide Substances 0.000 claims description 70
- 108020004705 Codon Proteins 0.000 claims description 66
- 230000028993 immune response Effects 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 19
- 241000124008 Mammalia Species 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 150000007523 nucleic acids Chemical group 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 230000024932 T cell mediated immunity Effects 0.000 claims description 3
- 230000028996 humoral immune response Effects 0.000 claims description 3
- 230000002500 effect on skin Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims 4
- 231100000765 toxin Toxicity 0.000 claims 4
- 108700012359 toxins Proteins 0.000 claims 4
- 230000000368 destabilizing effect Effects 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108010049048 Cholera Toxin Proteins 0.000 claims 1
- 102000009016 Cholera Toxin Human genes 0.000 claims 1
- 241000193163 Clostridioides difficile Species 0.000 claims 1
- 241000193155 Clostridium botulinum Species 0.000 claims 1
- 241000193468 Clostridium perfringens Species 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 1
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 1
- 101710146739 Enterotoxin Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108010081690 Pertussis Toxin Proteins 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 108090000848 Ubiquitin Proteins 0.000 claims 1
- 102000044159 Ubiquitin Human genes 0.000 claims 1
- 241000607479 Yersinia pestis Species 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000147 enterotoxin Substances 0.000 claims 1
- 231100000655 enterotoxin Toxicity 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98014507P | 2007-10-15 | 2007-10-15 | |
| US60/980,145 | 2007-10-15 | ||
| PCT/AU2008/001463 WO2009049350A1 (en) | 2007-10-15 | 2008-10-02 | Expression system for modulating an immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014097256A Division JP6155223B2 (ja) | 2007-10-15 | 2014-05-09 | 免疫応答をモジュレートするための発現系 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500035A JP2011500035A (ja) | 2011-01-06 |
| JP2011500035A5 true JP2011500035A5 (cg-RX-API-DMAC7.html) | 2012-02-02 |
| JP5543921B2 JP5543921B2 (ja) | 2014-07-09 |
Family
ID=40566909
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010529192A Active JP5543921B2 (ja) | 2007-10-15 | 2008-10-02 | 免疫応答をモジュレートするための発現系 |
| JP2010529193A Pending JP2011500036A (ja) | 2007-10-15 | 2008-10-02 | 構築物系およびその使用 |
| JP2014097256A Active JP6155223B2 (ja) | 2007-10-15 | 2014-05-09 | 免疫応答をモジュレートするための発現系 |
| JP2014147453A Pending JP2014221068A (ja) | 2007-10-15 | 2014-07-18 | 構築物系およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010529193A Pending JP2011500036A (ja) | 2007-10-15 | 2008-10-02 | 構築物系およびその使用 |
| JP2014097256A Active JP6155223B2 (ja) | 2007-10-15 | 2014-05-09 | 免疫応答をモジュレートするための発現系 |
| JP2014147453A Pending JP2014221068A (ja) | 2007-10-15 | 2014-07-18 | 構築物系およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9593340B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2215231A4 (cg-RX-API-DMAC7.html) |
| JP (4) | JP5543921B2 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2008314485B9 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2215269T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2662030T3 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2009049350A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3431099B1 (en) | 2007-03-30 | 2024-01-03 | The Research Foundation for The State University of New York | Attenuated viruses useful for vaccines |
| WO2009049350A1 (en) | 2007-10-15 | 2009-04-23 | The University Of Queensland | Expression system for modulating an immune response |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| US9795658B2 (en) | 2010-04-20 | 2017-10-24 | Admedus Vaccines Pty Ltd | Expression system for modulating an immune response |
| KR20190133290A (ko) | 2010-05-05 | 2019-12-02 | 뉴욕 유니버시티 | 스타필로코커스 아우레우스 류코시딘, 치료 조성물 및 그것의 용도 |
| EP2747778B1 (en) | 2011-08-26 | 2017-12-06 | Wisconsin Alumni Research Foundation | Influenza viruses with mutant pb2 gene segment as live attenuated vaccines |
| US9918724B2 (en) | 2012-12-27 | 2018-03-20 | Wright Medical Technology, Inc. | Ankle replacement system and method |
| JP2016522978A (ja) * | 2013-03-15 | 2016-08-04 | ダウ コーニング コーポレーションＤｏｗ Ｃｏｒｎｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ | 粉末形態の固体シリコーン含有ホットメルト組成物の堆積及びそのカプセル化材の形成を含む光学アセンブリの製造方法 |
| EP3054971B1 (en) * | 2013-10-11 | 2021-03-10 | The United States of America, represented by the Secretary, Department of Health and Human Services | Epstein-barr virus vaccines |
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| CN106999572A (zh) * | 2014-10-01 | 2017-08-01 | 阿德梅杜斯疫苗有限公司 | 用于诱导对单纯疱疹病毒2型(hsv‑2)的免疫应答的治疗组合物和方法 |
| WO2016086988A1 (en) * | 2014-12-03 | 2016-06-09 | Wageningen Universiteit | Optimisation of coding sequence for functional protein expression |
| EP3302532A4 (en) | 2015-06-05 | 2019-01-09 | New York University | COMPOSITIONS AND METHODS FOR BIOLOGICAL ACTIVE AGGREGATES AGAINST STAPHYLOKOKEN |
| US10724040B2 (en) | 2015-07-15 | 2020-07-28 | The Penn State Research Foundation | mRNA sequences to control co-translational folding of proteins |
| EP3362467A4 (en) | 2015-10-16 | 2019-06-12 | Kansas State University Research Foundation | IMMUNOGENIC COMPOSITIONS AGAINST PORCINE CIRCOVIRUS TYPE 3 AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| CN108601951B (zh) * | 2015-12-09 | 2022-11-22 | 金港医疗(澳大利亚)私人有限公司 | 用于治疗的免疫调节组合物 |
| US11197925B2 (en) | 2016-02-19 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Influenza B virus replication for vaccine development |
| US11197926B2 (en) | 2017-10-25 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| WO2019246286A1 (en) | 2018-06-19 | 2019-12-26 | Neon Therapeutics, Inc. | Neoantigens and uses thereof |
| WO2020033527A2 (en) | 2018-08-07 | 2020-02-13 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| WO2020041311A1 (en) * | 2018-08-20 | 2020-02-27 | Wisconsin Alumni Research Foundation | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein |
| EP3921413A1 (en) | 2019-02-08 | 2021-12-15 | Wisconsin Alumni Research Foundation (WARF) | Humanized cell line |
| US11701419B2 (en) * | 2019-04-04 | 2023-07-18 | Boehringer Ingelheim Animal Health USA Inc. | Porcine Circovirus Type 3 (PCV3) vaccines, and production and uses thereof |
| WO2020223699A1 (en) | 2019-05-01 | 2020-11-05 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
| WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
| WO2021150874A1 (en) | 2020-01-24 | 2021-07-29 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized na |
| CN113461799A (zh) * | 2020-03-18 | 2021-10-01 | 北京鼎成肽源生物技术有限公司 | 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用 |
| US12290562B2 (en) | 2020-03-25 | 2025-05-06 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| CN115704012A (zh) * | 2021-08-12 | 2023-02-17 | 中国科学院深圳先进技术研究院 | 一种含有降解决定子的重组病毒及其制备方法和应用 |
| CN117448254B (zh) * | 2023-10-23 | 2024-04-09 | 广州梵之容化妆品有限公司 | 一种光果甘草干细胞的制备方法及用途 |
| CN120060262B (zh) * | 2025-04-25 | 2025-08-12 | 中国农业科学院茶叶研究所 | 茶树CsU3启动子及其应用 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4184917A (en) * | 1974-04-01 | 1980-01-22 | Sandoz Ltd. | Process for producing a structurally modified interferon |
| US4321365A (en) * | 1977-10-19 | 1982-03-23 | Research Corporation | Oligonucleotides useful as adaptors in DNA cloning, adapted DNA molecules, and methods of preparing adaptors and adapted molecules |
| US4293652A (en) * | 1979-05-25 | 1981-10-06 | Cetus Corporation | Method for synthesizing DNA sequentially |
| US4351901A (en) * | 1980-03-24 | 1982-09-28 | Cetus Corporation | Method for single nucleotide alteration |
| US5036006A (en) * | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5100792A (en) * | 1984-11-13 | 1992-03-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues |
| US4945050A (en) * | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US4871488A (en) * | 1985-04-22 | 1989-10-03 | Albany Medical College Of Union University | Reconstituting viral glycoproteins into large phospholipid vesicles |
| US4663161A (en) * | 1985-04-22 | 1987-05-05 | Mannino Raphael J | Liposome methods and compositions |
| US5093242A (en) * | 1986-10-02 | 1992-03-03 | Massachusetts Institute Of Technology | Methods of generating desired amino-terminal residues in proteins |
| US4790824A (en) * | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5273876A (en) * | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
| DE10399032I1 (de) | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
| US5179022A (en) * | 1988-02-29 | 1993-01-12 | E. I. Du Pont De Nemours & Co. | Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner |
| CA2045129A1 (en) * | 1989-02-01 | 1990-08-02 | Alfred I. Geller | Herpes simplex virus type i expression vector |
| DK0737750T3 (da) | 1989-03-21 | 2003-09-01 | Vical Inc | Ekspression af exogene polynucleotidsekvenser i vertebrater |
| DE3909710A1 (de) * | 1989-03-23 | 1990-09-27 | Boehringer Mannheim Gmbh | Verfahren zur expression eines rekombinanten gens |
| GB8923123D0 (en) * | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| US5312335A (en) * | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) * | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| ATE162219T1 (de) | 1989-11-16 | 1998-01-15 | Univ Duke | Transformation von tierischen hautzellen mit hilfe von partikeln |
| FR2658432B1 (fr) | 1990-02-22 | 1994-07-01 | Medgenix Group Sa | Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation. |
| US5122463A (en) * | 1990-05-17 | 1992-06-16 | Massachusetts Institute Of Technology | Methods for trans-destabilization of specific proteins in vivo and dna molecules useful therefor |
| MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| EP1285967A3 (en) | 1990-09-21 | 2005-03-02 | Chiron Corporation | Human retroviral packaging cell line |
| EP0572401B2 (en) | 1991-02-19 | 2007-11-07 | The Regents of the University of California | Viral particles having altered host range |
| GB9105383D0 (en) * | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| US6013638A (en) * | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
| AU3972893A (en) * | 1992-04-03 | 1993-11-08 | Baylor College Of Medicine | Gene therapy using the intestine |
| US5383851A (en) * | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5831005A (en) * | 1992-09-24 | 1998-11-03 | Chiron Corporation | Synthesis of N-substituted oligomers |
| WO1994012629A1 (en) * | 1992-12-02 | 1994-06-09 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| US5654186A (en) * | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
| CA2160034C (en) * | 1993-04-06 | 2005-09-06 | Maribeth V. Eiden | Gibbon ape leukemia virus-based retroviral vectors |
| US6133028A (en) * | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
| US6120764A (en) * | 1993-06-24 | 2000-09-19 | Advec, Inc. | Adenoviruses for control of gene expression |
| US6140087A (en) * | 1993-06-24 | 2000-10-31 | Advec, Inc. | Adenovirus vectors for gene therapy |
| US5834441A (en) | 1993-09-13 | 1998-11-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral (AAV) liposomes and methods related thereto |
| US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| JPH07105638A (ja) * | 1993-10-05 | 1995-04-21 | Matsushita Electric Ind Co Ltd | 画像データの記録再生装置 |
| AU7353494A (en) * | 1993-11-12 | 1995-05-29 | Case Western Reserve University | Episomal expression vector for human gene therapy |
| CA2158733C (en) * | 1994-01-21 | 2007-01-16 | Dennis E. Mccabe | Gas driven gene delivery instrument |
| US5731172A (en) * | 1994-03-09 | 1998-03-24 | Sumitomo Pharmaceuticals Company, Ltd. | Recombinant adenovirus and process for producing the same |
| WO1995030019A1 (en) * | 1994-04-29 | 1995-11-09 | Pharmacia & Upjohn Company | Feline immunodeficiency virus vaccine |
| US5604090A (en) * | 1994-06-06 | 1997-02-18 | Fred Hutchinson Cancer Research Center | Method for increasing transduction of cells by adeno-associated virus vectors |
| US5786464C1 (en) * | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US5795737A (en) * | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
| US5693508A (en) * | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| GB9502879D0 (en) * | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
| JP3770333B2 (ja) * | 1995-03-15 | 2006-04-26 | 大日本住友製薬株式会社 | 組換えｄｎａウイルスおよびその製造方法 |
| GB9506782D0 (en) * | 1995-04-01 | 1995-05-24 | British Biotech Pharm | Retroviral vectors |
| CA2625279A1 (en) * | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
| US6013516A (en) * | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6004799A (en) * | 1996-03-05 | 1999-12-21 | The Regents Of The University Of California | Recombinant live feline immunodeficiency virus and proviral DNA vaccines |
| US5952221A (en) * | 1996-03-06 | 1999-09-14 | Avigen, Inc. | Adeno-associated virus vectors comprising a first and second nucleic acid sequence |
| US6818222B1 (en) * | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| US6287569B1 (en) * | 1997-04-10 | 2001-09-11 | The Regents Of The University Of California | Vaccines with enhanced intracellular processing |
| CA2288328A1 (en) | 1997-05-13 | 1998-11-19 | University Of North Carolina At Chapel Hill | Lentivirus-based gene transfer vectors |
| US5993412A (en) * | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| US6156303A (en) * | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| CA2296067C (en) * | 1997-07-09 | 2008-10-07 | The University Of Queensland | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
| AUPP807899A0 (en) * | 1999-01-08 | 1999-02-04 | University Of Queensland, The | Codon utilization |
| WO2000000600A2 (en) | 1997-09-22 | 2000-01-06 | Chang Lung Ji | Lentiviral vectors, comprising modified major donor splice sites and major packaging signals |
| ES2245042T3 (es) | 1997-09-24 | 2005-12-16 | The Regents Of The University Of California | Vectores de lentivirus de no primates y sistemas de empaquetamiento. |
| US7048929B1 (en) | 1997-11-10 | 2006-05-23 | Dana-Farber Cancer Institute, Inc. | Stabilized primate lentivirus envelope glycoproteins |
| WO1999030742A1 (en) | 1997-12-12 | 1999-06-24 | Luigi Naldini | Therapeutic use of lentiviral vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| WO1999051754A1 (en) | 1998-04-02 | 1999-10-14 | Dana-Farber Cancer Institute, Inc. | Infectious pseudotyped lentiviral vectors lacking matrix protein and uses thereof |
| AUPP807799A0 (en) | 1999-01-08 | 1999-02-04 | University Of Queensland, The | Polynucleotide and method |
| EP2196472A3 (en) | 1999-04-14 | 2011-04-13 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| ATE368122T1 (de) | 1999-04-29 | 2007-08-15 | Cell Genesys Inc | Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer |
| US6494865B1 (en) * | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
| WO2001081609A2 (en) | 2000-03-22 | 2001-11-01 | Chiron Corporation | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| JP2005502591A (ja) | 2001-01-12 | 2005-01-27 | カイロン コーポレイション | 核酸粘膜免疫 |
| EP2332573A1 (en) | 2001-05-31 | 2011-06-15 | Novartis Vaccines and Diagnostics, Inc. | Chimeric alphavirus replicon particles |
| AU2003258388C1 (en) | 2002-09-13 | 2010-03-18 | The University Of Queensland | Gene expression system based on codon translation efficiency |
| ES2346525T3 (es) * | 2002-11-08 | 2010-10-18 | The University Of Queensland | Un metodo para optimizar expresion genica utilizando optimizacion de condon sinonimo. |
| CA2658484A1 (en) * | 2006-07-20 | 2008-01-24 | Vical Incorporated | Compositions and methods for vaccinating against hsv-2 |
| WO2009049350A1 (en) | 2007-10-15 | 2009-04-23 | The University Of Queensland | Expression system for modulating an immune response |
| US9795658B2 (en) * | 2010-04-20 | 2017-10-24 | Admedus Vaccines Pty Ltd | Expression system for modulating an immune response |
-
2008
- 2008-10-02 WO PCT/AU2008/001463 patent/WO2009049350A1/en not_active Ceased
- 2008-10-02 JP JP2010529192A patent/JP5543921B2/ja active Active
- 2008-10-02 AU AU2008314485A patent/AU2008314485B9/en active Active
- 2008-10-02 DK DK08800100.3T patent/DK2215269T3/en active
- 2008-10-02 EP EP08800098A patent/EP2215231A4/en not_active Withdrawn
- 2008-10-02 ES ES08800100.3T patent/ES2662030T3/es active Active
- 2008-10-02 WO PCT/AU2008/001465 patent/WO2009049351A1/en not_active Ceased
- 2008-10-02 AU AU2008314486A patent/AU2008314486B2/en active Active
- 2008-10-02 EP EP08800100.3A patent/EP2215269B1/en active Active
- 2008-10-02 US US12/738,284 patent/US9593340B2/en active Active
- 2008-10-02 JP JP2010529193A patent/JP2011500036A/ja active Pending
- 2008-10-02 US US12/738,291 patent/US20120040367A1/en not_active Abandoned
-
2014
- 2014-05-09 JP JP2014097256A patent/JP6155223B2/ja active Active
- 2014-07-18 JP JP2014147453A patent/JP2014221068A/ja active Pending
-
2017
- 2017-01-17 US US15/408,201 patent/US20170218393A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500035A5 (cg-RX-API-DMAC7.html) | ||
| US20220125912A1 (en) | Vaccine against rsv | |
| CN107434827B (zh) | 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 | |
| US20210275664A1 (en) | Prefusion coronavirus spike proteins and their use | |
| CN105408348B (zh) | 稳定化的可溶性融合前rsv f多肽 | |
| JP2024160321A (ja) | パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用 | |
| JP2013529077A5 (cg-RX-API-DMAC7.html) | ||
| JP2013529078A5 (cg-RX-API-DMAC7.html) | ||
| JP6505110B2 (ja) | ＯｓｐＡの突然変異体断片、並びにそれに関する方法および使用 | |
| CN105188745A (zh) | 稳定化的可溶性融合前rsv f多肽 | |
| WO2017005848A1 (en) | Stabilized soluble pre-fusion rsv f polypeptides | |
| JP2011528222A5 (cg-RX-API-DMAC7.html) | ||
| CN106061995A (zh) | Uspa2蛋白质构建体及其用途 | |
| CN103687617A (zh) | 作为过敏症疫苗的肽载体融合蛋白 | |
| HRP20170094T1 (hr) | Imunogeni pripravak | |
| EP3279217A1 (en) | Streptococcus pneumoniae protein antigen, and preparation method and use thereof | |
| CN107847575A (zh) | 用于猪生殖与呼吸综合症及猪圆环病毒相关疾病的疫苗组合物 | |
| AU2021269320A1 (en) | Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein a | |
| JP2012516140A5 (cg-RX-API-DMAC7.html) | ||
| CN100582122C (zh) | O型口蹄疫病毒多表位粘膜免疫疫苗及其应用 | |
| AU2025205220A1 (en) | Vaccine polypeptide compositions and methods | |
| RU2005101744A (ru) | Последовательность днк и получение аллергена пыльцы трав ph1 p4 с помощью рекомбинантных способов | |
| Quintana-Vázquez et al. | Recombinant hybrid proteins from pertactin type 1 and 2 of Bordetella pertussis are more immunogenic in mice than the original molecules | |
| CN102516373B (zh) | 去除人同源性的肺炎链球菌表面蛋白a、纯化方法及用途 | |
| WO2002000695A2 (en) | Peptides for the preparation of vaccines against bordetella pertussis and bordetella parapertussis |